236 related articles for article (PubMed ID: 31589171)
21. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
[TBL] [Abstract][Full Text] [Related]
22. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
Pirenne F; Bartolucci P; Habibi A
Transfus Clin Biol; 2017 Sep; 24(3):227-231. PubMed ID: 28669521
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
Aygun B; Padmanabhan S; Paley C; Chandrasekaran V
Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
[TBL] [Abstract][Full Text] [Related]
24. Delayed hemolytic transfusion reaction in children with sickle cell disease.
de Montalembert M; Dumont MD; Heilbronner C; Brousse V; Charrara O; Pellegrino B; Piguet C; Soussan V; Noizat-Pirenne F
Haematologica; 2011 Jun; 96(6):801-7. PubMed ID: 21330322
[TBL] [Abstract][Full Text] [Related]
25. [Delayed hemolytic transfusion reaction in sicle cell disease patients: a new challenge for the Hemovigilance network].
Rieux C; De Meyer E; Boudjedir K
Transfus Clin Biol; 2015 Mar; 22(1):37-41. PubMed ID: 25441454
[TBL] [Abstract][Full Text] [Related]
26. Prevention of delayed hemolytic transfusion reaction.
Pirenne F
Transfus Clin Biol; 2019 May; 26(2):99-101. PubMed ID: 30926306
[TBL] [Abstract][Full Text] [Related]
27. Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease.
Dean CL; Maier CL; Roback JD; Stowell SR
Transfusion; 2019 Feb; 59(2):448-453. PubMed ID: 30412270
[TBL] [Abstract][Full Text] [Related]
28. Anti-N and anti-Do
Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
[TBL] [Abstract][Full Text] [Related]
29. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease.
Mekontso Dessap A; Pirenne F; Razazi K; Moutereau S; Abid S; Brun-Buisson C; Maitre B; Michel M; Galacteros F; Bartolucci P; Habibi A
Am J Hematol; 2016 Dec; 91(12):1181-1184. PubMed ID: 27538126
[TBL] [Abstract][Full Text] [Related]
30. Preventing delayed hemolytic transfusion reactions in sickle cell disease.
Castro O; Oneal P; Medina A; Onojobi G; Gordeuk VR
Transfusion; 2016 Nov; 56(11):2899-2900. PubMed ID: 28211954
[No Abstract] [Full Text] [Related]
31. Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome.
Lukin R; Law JY; Lokhandwala PM
Transfus Apher Sci; 2024 Jun; 63(3):103919. PubMed ID: 38582651
[TBL] [Abstract][Full Text] [Related]
32. Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease.
Pal M; Bao W; Wang R; Liu Y; An X; Mitchell WB; Lobo CA; Minniti C; Shi PA; Manwani D; Yazdanbakhsh K; Zhong H
Blood; 2021 Jan; 137(2):269-280. PubMed ID: 33152749
[TBL] [Abstract][Full Text] [Related]
33. Managing pregnancy in patients with sickle cell disease from a transfusion perspective.
Habibi A; Benachi A; Lecarpentier E
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):640-645. PubMed ID: 38066847
[TBL] [Abstract][Full Text] [Related]
34. [Risks associated with transfusions in sickle cell disease: delayed hemolytic transfusion reaction].
Habibi A; Noizat-Pirenne F
Rev Prat; 2014 Oct; 64(8):1128-9. PubMed ID: 25510142
[No Abstract] [Full Text] [Related]
35. Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
Lapite A; Bhar S; Fasipe T
Pediatr Blood Cancer; 2024 Aug; 71(8):e31061. PubMed ID: 38840429
[TBL] [Abstract][Full Text] [Related]
36. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
Vidler JB; Gardner K; Amenyah K; Mijovic A; Thein SL
Br J Haematol; 2015 Jun; 169(5):746-53. PubMed ID: 25753472
[TBL] [Abstract][Full Text] [Related]
37. Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients.
Dean CL; Maier CL; Chonat S; Chang A; Carden MA; El Rassi F; McLemore ML; Stowell SR; Fasano RM
Transfusion; 2019 May; 59(5):1698-1705. PubMed ID: 30848512
[TBL] [Abstract][Full Text] [Related]
38. Principles and problems of transfusion in sickle cell disease.
Telen MJ
Semin Hematol; 2001 Oct; 38(4):315-23. PubMed ID: 11605166
[TBL] [Abstract][Full Text] [Related]
39. Transfusion-transmitted malaria masquerading as sickle cell crisis with multisystem organ failure.
Maier CL; Gross PJ; Dean CL; Chonat S; Ip A; McLemore M; El Rassi F; Stowell SR; Josephson CD; Fasano RM
Transfusion; 2018 Jun; 58(6):1550-1554. PubMed ID: 29524230
[TBL] [Abstract][Full Text] [Related]
40. Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.
Ibanez C; Habibi A; Mekontso-Dessap A; Chadebech P; Chami B; Bierling P; Galactéros F; Rieux C; Nataf J; Bartolucci P; Peyrard T; Pirenne F
Transfusion; 2016 Jul; 56(7):1828-33. PubMed ID: 27145018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
